clinical trial · NCT03895996
Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes
Type 1 Diabetes MellitusAVT001Placebo
brief summary
This is a double-blind, randomized , placebo-controlled study to evaluate the safety and tolerability of AVT001, and to assess AVT001 as a potential treatment for type 1 diabetes (T1D). The trial will involve approximately 24 new-onset T1D subjects.
started
Jun 20, 2019
primary completion
May 17, 2022
completion
Dec 19, 2023
last updated
Mar 5, 2025
official title
A Phase 1 / 2 Double-Blind, Randomized, Placebo Controlled Study of Safety, Tolerability and Potential Efficacy of AVOTRES Cell-Based Therapy (AVT001) in Patients With Type 1 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol